Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

Open Access Correction

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

Erika Hamilton1, Kimberly Blackwell1, Amy C Hobeika2, Timothy M Clay3, Gloria Broadwater4, Xiu-Rong Ren5, Wei Chen5, Henry Castro3, Frederic Lehmann3, Neil Spector1, Junping Wei6, Takuya Osada6, H Kim Lyerly2 and Michael A Morse1*

Author Affiliations

1 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA

2 Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA

3 GlaxoSmithKline Biologicals, Rixensart, Belgium

4 Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA

5 Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA

6 Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA

For all author emails, please log on.

Journal of Translational Medicine 2013, 11:82  doi:10.1186/1479-5876-11-82


The electronic version of this article is the complete one and can be found online at: http://www.translational-medicine.com/content/11/1/82


Received:26 March 2013
Accepted:26 March 2013
Published:27 March 2013

© 2013 Hamilton et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corrections

In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors’ list. Therefore the correct author list should be:

Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly and Michael A Morse.

Also the title of our original manuscript ‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion’ is also incorrect. The title should read:‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition’.

Journal of Translational Medicine regret any inconvenience that this inaccuracy might have caused.

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

All authors read and approved the final manuscript.

References

  1. Hamilton : Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.

    J Transl Med 2012, 10:28. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL